DNase I as Treatment for MPO-ANCA Vasculitis

DNase I 治疗 MPO-ANCA 血管炎

• 批准号: nhmrc : 1146892
• 负责人: Prof Stephen Holdsworth
• 金额: $ 58.71万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dnase-i-treatment-anca-vasculitis/1320754
• 关键词: DNase; Treatment; MPO; ANCA; Vasculitis

MPO-ANCA GN is a major cause of renal failure. Current treatments are toxic and poorly effective. Excessive DNA production resulting in prominent deposits of extracellular DNA are seen in glomeruli of patients with MPO-ANCA GN. This study will look at the pathological role of DNA and in a relevant animal model, use DNase I treatment to dissolve deposited DNA and treat anti-MPO autoimmunity and GN. This evidence will allow the introduction of DNase I in clinical trials.

MPO-ANCA GN是肾衰竭的主要原因。目前的治疗方法有毒且效果不佳。在MPO-ANCA GN患者的肾小球中可以看到过量的DNA产生导致细胞外DNA的显著沉积。本研究将研究DNA的病理作用，并在相关的动物模型中，使用DNase I治疗来溶解沉积的DNA并治疗抗mpo自身免疫和GN。这一证据将允许在临床试验中引入DNase I。